View ValuationStella Pharma 将来の成長Future 基準チェック /06現在、 Stella Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長13.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Feb 11Stella Pharma Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2023Stella Pharma Corporation provided earnings guidance for the full year ending March 31, 2023. For the year, the company expects net sales of ¥220 million, operating loss of ¥850 million, loss of ¥823 million and loss per share of ¥28.55.すべての更新を表示Recent updatesお知らせ • Jun 24Stella Pharma Corporation announced that it has received ¥318.2155 million in funding from CVI Investments, Inc.On June 22, 2026, Stella Pharma Corporation has closed the transaction.お知らせ • Jun 09Stella Pharma Corporation to Report Q1, 2027 Results on Aug 06, 2026Stella Pharma Corporation announced that they will report Q1, 2027 results on Aug 06, 2026Reported Earnings • May 17Full year 2026 earnings released: JP¥22.93 loss per share (vs JP¥4.19 loss in FY 2025)Full year 2026 results: JP¥22.93 loss per share (further deteriorated from JP¥4.19 loss in FY 2025). Net loss: JP¥780.0m (loss widened 457% from FY 2025). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.New Risk • May 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.4b (US$91.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risk Market cap is less than US$100m (JP¥14.4b market cap, or US$91.2m).お知らせ • May 13Stella Pharma Corporation, Annual General Meeting, Jun 24, 2026Stella Pharma Corporation, Annual General Meeting, Jun 24, 2026.Reported Earnings • Feb 14Third quarter 2026 earnings released: JP¥6.03 loss per share (vs JP¥3.09 loss in 3Q 2025)Third quarter 2026 results: JP¥6.03 loss per share (further deteriorated from JP¥3.09 loss in 3Q 2025). Revenue: JP¥61.0m (down 28% from 3Q 2025). Net loss: JP¥205.0m (loss widened 95% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.分析記事 • Dec 22Does Stella Pharma (TSE:4888) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Market cap is less than US$100m (JP¥8.51b market cap, or US$54.4m).Reported Earnings • Nov 17Second quarter 2026 earnings released: JP¥4.44 loss per share (vs JP¥3.16 loss in 2Q 2025)Second quarter 2026 results: JP¥4.44 loss per share (further deteriorated from JP¥3.16 loss in 2Q 2025). Revenue: JP¥108.0m (flat on 2Q 2025). Net loss: JP¥151.0m (loss widened 41% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 08First quarter 2026 earnings released: JP¥4.59 loss per share (vs JP¥5.09 loss in 1Q 2025)First quarter 2026 results: JP¥4.59 loss per share (improved from JP¥5.09 loss in 1Q 2025). Revenue: JP¥92.0m (up 51% from 1Q 2025). Net loss: JP¥156.0m (loss narrowed 3.1% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jun 14+ 2 more updatesStella Pharma Corporation to Report Q1, 2026 Results on Aug 07, 2025Stella Pharma Corporation announced that they will report Q1, 2026 results on Aug 07, 2025Buy Or Sell Opportunity • Jun 09Now 24% overvaluedOver the last 90 days, the stock has fallen 4.1% to JP¥371. The fair value is estimated to be JP¥299, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 55% over the last 3 years. Earnings per share has grown by 17%.Buy Or Sell Opportunity • May 23Now 21% overvaluedOver the last 90 days, the stock has fallen 28% to JP¥360. The fair value is estimated to be JP¥299, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 55% over the last 3 years. Earnings per share has grown by 17%.Reported Earnings • May 12Full year 2025 earnings released: JP¥4.19 loss per share (vs JP¥24.63 loss in FY 2024)Full year 2025 results: JP¥4.19 loss per share (improved from JP¥24.63 loss in FY 2024). Revenue: JP¥961.0m (up 257% from FY 2024). Net loss: JP¥140.0m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • May 09Stella Pharma Corporation, Annual General Meeting, Jun 24, 2025Stella Pharma Corporation, Annual General Meeting, Jun 24, 2025.お知らせ • Mar 05Stella Pharma Corporation to Report Fiscal Year 2025 Results on May 09, 2025Stella Pharma Corporation announced that they will report fiscal year 2025 results on May 09, 2025Reported Earnings • Feb 14Third quarter 2025 earnings released: JP¥3.09 loss per share (vs JP¥5.25 loss in 3Q 2024)Third quarter 2025 results: JP¥3.09 loss per share (improved from JP¥5.25 loss in 3Q 2024). Net loss: JP¥105.0m (loss narrowed 36% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.分析記事 • Feb 13Is Stella Pharma (TSE:4888) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Feb 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.5b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Revenue is less than US$5m (JP¥285m revenue, or US$1.8m). Market cap is less than US$100m (JP¥15.5b market cap, or US$99.9m).お知らせ • Jan 03Stella Pharma Corporation to Report Q3, 2025 Results on Feb 12, 2025Stella Pharma Corporation announced that they will report Q3, 2025 results on Feb 12, 2025Reported Earnings • Nov 10Second quarter 2025 earnings released: JP¥3.16 loss per share (vs JP¥4.51 loss in 2Q 2024)Second quarter 2025 results: JP¥3.16 loss per share (improved from JP¥4.51 loss in 2Q 2024). Net loss: JP¥107.0m (loss narrowed 24% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Sep 27Stella Pharma Corporation to Report Q2, 2025 Results on Nov 08, 2024Stella Pharma Corporation announced that they will report Q2, 2025 results on Nov 08, 2024お知らせ • Jun 22Stella Pharma Corporation to Report Q1, 2025 Results on Aug 07, 2024Stella Pharma Corporation announced that they will report Q1, 2025 results on Aug 07, 2024Reported Earnings • May 14Full year 2024 earnings released: JP¥24.63 loss per share (vs JP¥26.94 loss in FY 2023)Full year 2024 results: JP¥24.63 loss per share (improved from JP¥26.94 loss in FY 2023). Net loss: JP¥763.0m (loss narrowed 1.9% from FY 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • May 12Stella Pharma Corporation, Annual General Meeting, Jun 25, 2024Stella Pharma Corporation, Annual General Meeting, Jun 25, 2024.お知らせ • Mar 24Stella Pharma Corporation to Report Fiscal Year 2024 Results on May 10, 2024Stella Pharma Corporation announced that they will report fiscal year 2024 results on May 10, 2024Reported Earnings • Feb 15Third quarter 2024 earnings released: JP¥5.25 loss per share (vs JP¥4.85 loss in 3Q 2023)Third quarter 2024 results: JP¥5.25 loss per share (further deteriorated from JP¥4.85 loss in 3Q 2023). Net loss: JP¥164.0m (loss widened 18% from 3Q 2023).お知らせ • Dec 27Stella Pharma Corporation to Report Q3, 2024 Results on Feb 13, 2024Stella Pharma Corporation announced that they will report Q3, 2024 results on Feb 13, 2024Reported Earnings • Nov 10Second quarter 2024 earnings released: JP¥4.51 loss per share (vs JP¥5.16 loss in 2Q 2023)Second quarter 2024 results: JP¥4.51 loss per share (improved from JP¥5.16 loss in 2Q 2023). Net loss: JP¥140.0m (loss narrowed 5.4% from 2Q 2023).お知らせ • Sep 27Stella Pharma Corporation to Report Q2, 2024 Results on Nov 09, 2023Stella Pharma Corporation announced that they will report Q2, 2024 results on Nov 09, 2023Reported Earnings • Aug 10First quarter 2024 earnings released: JP¥5.43 loss per share (vs JP¥6.84 loss in 1Q 2023)First quarter 2024 results: JP¥5.43 loss per share (improved from JP¥6.84 loss in 1Q 2023). Net loss: JP¥165.0m (loss narrowed 16% from 1Q 2023).お知らせ • Jun 28Stella Pharma Corporation to Report Q1, 2024 Results on Aug 09, 2023Stella Pharma Corporation announced that they will report Q1, 2024 results on Aug 09, 2023Reported Earnings • May 10Full year 2023 earnings released: JP¥26.94 loss per share (vs JP¥27.31 loss in FY 2022)Full year 2023 results: JP¥26.94 loss per share. Net loss: JP¥778.0m (loss widened 1.4% from FY 2022).お知らせ • May 10Stella Pharma Corporation, Annual General Meeting, Jun 27, 2023Stella Pharma Corporation, Annual General Meeting, Jun 27, 2023.Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥4.85 loss per share (vs JP¥5.31 loss in 3Q 2022)Third quarter 2023 results: JP¥4.85 loss per share (improved from JP¥5.31 loss in 3Q 2022). Net loss: JP¥139.0m (loss narrowed 8.6% from 3Q 2022).お知らせ • Feb 11Stella Pharma Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2023Stella Pharma Corporation provided earnings guidance for the full year ending March 31, 2023. For the year, the company expects net sales of ¥220 million, operating loss of ¥850 million, loss of ¥823 million and loss per share of ¥28.55.お知らせ • Dec 26Stella Pharma Corporation to Report Q3, 2023 Results on Feb 10, 2023Stella Pharma Corporation announced that they will report Q3, 2023 results on Feb 10, 2023Reported Earnings • Nov 19First half 2023 earnings releasedFirst half 2023 results: JP¥12.00 loss per share. Net loss: JP¥344.0m (flat on 1H 2022).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 11First half 2023 earnings releasedFirst half 2023 results: JP¥12.00 loss per share. Net loss: JP¥344.0m (flat on 1H 2022).お知らせ • Sep 24Stella Pharma Corporation to Report Q2, 2023 Results on Nov 11, 2022Stella Pharma Corporation announced that they will report Q2, 2023 results on Nov 11, 2022お知らせ • May 12Stella Pharma Corporation, Annual General Meeting, Jun 29, 2022Stella Pharma Corporation, Annual General Meeting, Jun 29, 2022.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 08Stella Pharma Corporation to Report Fiscal Year 2022 Results on May 10, 2022Stella Pharma Corporation announced that they will report fiscal year 2022 results on May 10, 2022 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Stella Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:4888 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026323-780-345-334N/A12/31/2025968-279N/AN/AN/A9/30/2025992-179-735-725N/A6/30/2025992-135N/AN/AN/A3/31/2025961-140128140N/A12/31/2024323-667N/AN/AN/A9/30/2024285-72693104N/A6/30/2024269-759N/AN/AN/A3/31/2024269-763-886-876N/A12/31/2023254-764N/AN/AN/A9/30/2023290-739-920-905N/A6/30/2023244-747N/AN/AN/A3/31/2023229-778-856-827N/A12/31/2022191-690N/AN/AN/A9/30/2022123-703-861-832N/A6/30/2022139-741N/AN/AN/A3/31/2022100-767-1,127-1,081N/A12/31/2021134-715N/AN/AN/A3/31/2021205-659-794-772N/A3/31/2020N/A-962N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4888の予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4888の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4888の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4888の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4888の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4888の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/20 18:30終値2026/07/17 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Stella Pharma Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 11Stella Pharma Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2023Stella Pharma Corporation provided earnings guidance for the full year ending March 31, 2023. For the year, the company expects net sales of ¥220 million, operating loss of ¥850 million, loss of ¥823 million and loss per share of ¥28.55.
お知らせ • Jun 24Stella Pharma Corporation announced that it has received ¥318.2155 million in funding from CVI Investments, Inc.On June 22, 2026, Stella Pharma Corporation has closed the transaction.
お知らせ • Jun 09Stella Pharma Corporation to Report Q1, 2027 Results on Aug 06, 2026Stella Pharma Corporation announced that they will report Q1, 2027 results on Aug 06, 2026
Reported Earnings • May 17Full year 2026 earnings released: JP¥22.93 loss per share (vs JP¥4.19 loss in FY 2025)Full year 2026 results: JP¥22.93 loss per share (further deteriorated from JP¥4.19 loss in FY 2025). Net loss: JP¥780.0m (loss widened 457% from FY 2025). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
New Risk • May 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.4b (US$91.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risk Market cap is less than US$100m (JP¥14.4b market cap, or US$91.2m).
お知らせ • May 13Stella Pharma Corporation, Annual General Meeting, Jun 24, 2026Stella Pharma Corporation, Annual General Meeting, Jun 24, 2026.
Reported Earnings • Feb 14Third quarter 2026 earnings released: JP¥6.03 loss per share (vs JP¥3.09 loss in 3Q 2025)Third quarter 2026 results: JP¥6.03 loss per share (further deteriorated from JP¥3.09 loss in 3Q 2025). Revenue: JP¥61.0m (down 28% from 3Q 2025). Net loss: JP¥205.0m (loss widened 95% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
分析記事 • Dec 22Does Stella Pharma (TSE:4888) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Market cap is less than US$100m (JP¥8.51b market cap, or US$54.4m).
Reported Earnings • Nov 17Second quarter 2026 earnings released: JP¥4.44 loss per share (vs JP¥3.16 loss in 2Q 2025)Second quarter 2026 results: JP¥4.44 loss per share (further deteriorated from JP¥3.16 loss in 2Q 2025). Revenue: JP¥108.0m (flat on 2Q 2025). Net loss: JP¥151.0m (loss widened 41% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 08First quarter 2026 earnings released: JP¥4.59 loss per share (vs JP¥5.09 loss in 1Q 2025)First quarter 2026 results: JP¥4.59 loss per share (improved from JP¥5.09 loss in 1Q 2025). Revenue: JP¥92.0m (up 51% from 1Q 2025). Net loss: JP¥156.0m (loss narrowed 3.1% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jun 14+ 2 more updatesStella Pharma Corporation to Report Q1, 2026 Results on Aug 07, 2025Stella Pharma Corporation announced that they will report Q1, 2026 results on Aug 07, 2025
Buy Or Sell Opportunity • Jun 09Now 24% overvaluedOver the last 90 days, the stock has fallen 4.1% to JP¥371. The fair value is estimated to be JP¥299, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 55% over the last 3 years. Earnings per share has grown by 17%.
Buy Or Sell Opportunity • May 23Now 21% overvaluedOver the last 90 days, the stock has fallen 28% to JP¥360. The fair value is estimated to be JP¥299, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 55% over the last 3 years. Earnings per share has grown by 17%.
Reported Earnings • May 12Full year 2025 earnings released: JP¥4.19 loss per share (vs JP¥24.63 loss in FY 2024)Full year 2025 results: JP¥4.19 loss per share (improved from JP¥24.63 loss in FY 2024). Revenue: JP¥961.0m (up 257% from FY 2024). Net loss: JP¥140.0m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • May 09Stella Pharma Corporation, Annual General Meeting, Jun 24, 2025Stella Pharma Corporation, Annual General Meeting, Jun 24, 2025.
お知らせ • Mar 05Stella Pharma Corporation to Report Fiscal Year 2025 Results on May 09, 2025Stella Pharma Corporation announced that they will report fiscal year 2025 results on May 09, 2025
Reported Earnings • Feb 14Third quarter 2025 earnings released: JP¥3.09 loss per share (vs JP¥5.25 loss in 3Q 2024)Third quarter 2025 results: JP¥3.09 loss per share (improved from JP¥5.25 loss in 3Q 2024). Net loss: JP¥105.0m (loss narrowed 36% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
分析記事 • Feb 13Is Stella Pharma (TSE:4888) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Feb 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.5b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Revenue is less than US$5m (JP¥285m revenue, or US$1.8m). Market cap is less than US$100m (JP¥15.5b market cap, or US$99.9m).
お知らせ • Jan 03Stella Pharma Corporation to Report Q3, 2025 Results on Feb 12, 2025Stella Pharma Corporation announced that they will report Q3, 2025 results on Feb 12, 2025
Reported Earnings • Nov 10Second quarter 2025 earnings released: JP¥3.16 loss per share (vs JP¥4.51 loss in 2Q 2024)Second quarter 2025 results: JP¥3.16 loss per share (improved from JP¥4.51 loss in 2Q 2024). Net loss: JP¥107.0m (loss narrowed 24% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Sep 27Stella Pharma Corporation to Report Q2, 2025 Results on Nov 08, 2024Stella Pharma Corporation announced that they will report Q2, 2025 results on Nov 08, 2024
お知らせ • Jun 22Stella Pharma Corporation to Report Q1, 2025 Results on Aug 07, 2024Stella Pharma Corporation announced that they will report Q1, 2025 results on Aug 07, 2024
Reported Earnings • May 14Full year 2024 earnings released: JP¥24.63 loss per share (vs JP¥26.94 loss in FY 2023)Full year 2024 results: JP¥24.63 loss per share (improved from JP¥26.94 loss in FY 2023). Net loss: JP¥763.0m (loss narrowed 1.9% from FY 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • May 12Stella Pharma Corporation, Annual General Meeting, Jun 25, 2024Stella Pharma Corporation, Annual General Meeting, Jun 25, 2024.
お知らせ • Mar 24Stella Pharma Corporation to Report Fiscal Year 2024 Results on May 10, 2024Stella Pharma Corporation announced that they will report fiscal year 2024 results on May 10, 2024
Reported Earnings • Feb 15Third quarter 2024 earnings released: JP¥5.25 loss per share (vs JP¥4.85 loss in 3Q 2023)Third quarter 2024 results: JP¥5.25 loss per share (further deteriorated from JP¥4.85 loss in 3Q 2023). Net loss: JP¥164.0m (loss widened 18% from 3Q 2023).
お知らせ • Dec 27Stella Pharma Corporation to Report Q3, 2024 Results on Feb 13, 2024Stella Pharma Corporation announced that they will report Q3, 2024 results on Feb 13, 2024
Reported Earnings • Nov 10Second quarter 2024 earnings released: JP¥4.51 loss per share (vs JP¥5.16 loss in 2Q 2023)Second quarter 2024 results: JP¥4.51 loss per share (improved from JP¥5.16 loss in 2Q 2023). Net loss: JP¥140.0m (loss narrowed 5.4% from 2Q 2023).
お知らせ • Sep 27Stella Pharma Corporation to Report Q2, 2024 Results on Nov 09, 2023Stella Pharma Corporation announced that they will report Q2, 2024 results on Nov 09, 2023
Reported Earnings • Aug 10First quarter 2024 earnings released: JP¥5.43 loss per share (vs JP¥6.84 loss in 1Q 2023)First quarter 2024 results: JP¥5.43 loss per share (improved from JP¥6.84 loss in 1Q 2023). Net loss: JP¥165.0m (loss narrowed 16% from 1Q 2023).
お知らせ • Jun 28Stella Pharma Corporation to Report Q1, 2024 Results on Aug 09, 2023Stella Pharma Corporation announced that they will report Q1, 2024 results on Aug 09, 2023
Reported Earnings • May 10Full year 2023 earnings released: JP¥26.94 loss per share (vs JP¥27.31 loss in FY 2022)Full year 2023 results: JP¥26.94 loss per share. Net loss: JP¥778.0m (loss widened 1.4% from FY 2022).
お知らせ • May 10Stella Pharma Corporation, Annual General Meeting, Jun 27, 2023Stella Pharma Corporation, Annual General Meeting, Jun 27, 2023.
Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥4.85 loss per share (vs JP¥5.31 loss in 3Q 2022)Third quarter 2023 results: JP¥4.85 loss per share (improved from JP¥5.31 loss in 3Q 2022). Net loss: JP¥139.0m (loss narrowed 8.6% from 3Q 2022).
お知らせ • Feb 11Stella Pharma Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2023Stella Pharma Corporation provided earnings guidance for the full year ending March 31, 2023. For the year, the company expects net sales of ¥220 million, operating loss of ¥850 million, loss of ¥823 million and loss per share of ¥28.55.
お知らせ • Dec 26Stella Pharma Corporation to Report Q3, 2023 Results on Feb 10, 2023Stella Pharma Corporation announced that they will report Q3, 2023 results on Feb 10, 2023
Reported Earnings • Nov 19First half 2023 earnings releasedFirst half 2023 results: JP¥12.00 loss per share. Net loss: JP¥344.0m (flat on 1H 2022).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 11First half 2023 earnings releasedFirst half 2023 results: JP¥12.00 loss per share. Net loss: JP¥344.0m (flat on 1H 2022).
お知らせ • Sep 24Stella Pharma Corporation to Report Q2, 2023 Results on Nov 11, 2022Stella Pharma Corporation announced that they will report Q2, 2023 results on Nov 11, 2022
お知らせ • May 12Stella Pharma Corporation, Annual General Meeting, Jun 29, 2022Stella Pharma Corporation, Annual General Meeting, Jun 29, 2022.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 08Stella Pharma Corporation to Report Fiscal Year 2022 Results on May 10, 2022Stella Pharma Corporation announced that they will report fiscal year 2022 results on May 10, 2022